Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 20, 2002, Pages 4261-4267

  Hainsworth, John D ^a   Litchy, Sharlene ^a   Burris III, Howard A ^a   Scullin Jr , Daniel C ^a   Corso, Steven W ^a   Yardley, Denise A ^a   Morrissey, Lisa ^a   Greco, F Anthony ^a  

^a SC

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HYPOTENSION; LYMPHOCYTOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0037108822     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.674     Document Type: Article

References (21)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:L2188-L2195, 1997
3. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
4. Hainsworth JD, Burris HA III, Morrissey LH, et al: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 95:3052-3056. 2000
5. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
6. Mantel N, Haenszel W: Statistical aspects of the analysis of data from the retrospective study of disease. J Natl Cancer Inst 27:719-748, 1959
7. The Non-Hodgkin's Lymphoma Prognostic Factors Project: Development of a predictive model for aggressive lymphoma: The International NHL Prognostic Factors Project. N Engl J Med 329:987-994, 1993
8. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
9. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
10. Foran JM, Rohatiner AZS. Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
11. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
12. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001
13. Keating MJ, O'Brien S, Cortes J, et al: Fludarabine and cyclophosphamide combined with Rituxan is a potent cytoreductive regimen as initial therapy of chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 19:8a, 2000 (abstr 21)
14. Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40:259-263, 1992
15. Bannerji R, Pearson M, Flinn IW, et al: Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy. Blood 96:167a, 2000 (abstr 706)
16. Weng WK, Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin's lymphoma. Blood 98:1352-1357, 2001
17. Scott SD, Hetherington N, Link BK: The cost-effectiveness of treatment with rituximab compared to fludarabine for relapsed or refractory low-grade-follicular NHL. Proc Am Soc Clin Oncol 19:452a. 2000 (abstr 1772)
18. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
19. Garcia-Conde J. Conde E, Sierra J, et al: Rituximab (IDEC-C2B8) and CVP chemotherapy in follicular or low grade B-cell lymphoma after relapse: Results after 6 months of follow-up. Proc Am Soc Clin Oncol 19:27a, 2000 (abstr 96)
20. Czuczman MS, Fallon A, Scarpace A, et al: Phase II study of rituximab in combination with fludarabine in patients with low grade or follicular B-cell lymphoma. Blood 96:729a, 2000 (abstr 3154)
21. Cabanillas F, McLaughlin P, Hagemeister F, et al: Molecular responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma. Blood 96:331a, 2000 (abstr 1429)